- Home
- DXLG vs BDSX Comparison
DXLG vs BDSX Comparison
Compare DXLG & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | BDSX |
|---|---|---|
| Founded | 1976 | 2005 |
| Country | United States | United States |
| Employees | N/A | 273 |
| Industry | Clothing/Shoe/Accessory Stores | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 122.0M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DXLG | BDSX |
|---|---|---|
| Price | $0.51 | $15.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.50 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 127.3K | 122.8K |
| Earning Date | 04-14-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,015,000.00 | $88,499,000.00 |
| Revenue This Year | N/A | $22.01 |
| Revenue Next Year | $3.24 | $26.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.49 | $0.25 |
| 52 Week High | $2.11 | $17.40 |
Technical Indicators
Market Signals| Indicator | DXLG | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 75.40 |
| Support Level | N/A | $6.33 |
| Resistance Level | $0.73 | N/A |
| Average True Range (ATR) | 0.07 | 1.66 |
| MACD | 0.00 | 0.29 |
| Stochastic Oscillator | 14.45 | 75.30 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.